Partner with us

Join us to advance best-in-class, organ-specific precision biologics for immune and inflammatory diseases.

TregShield Bio is actively seeking partners and investors to advance our platform and pipeline.

TregShield Bio is advancing a disruptive platform designed to reshape the immune and inflammatory disease landscape. We are actively seeking investors and strategic partners who share our mission of bringing transformative, precision-activated biologics to patients in need.

Whether you’re a biopharmaceutical company looking to enhance the therapeutic window of your pipeline assets or an investor seeking to support the next frontier in biologics, we are eager to collaborate.

Why partner with TregShield Bio?

• Proprietary tissue-activable technology with broad potential across autoimmune indications
• Lead Discovery asset (TRS-001) addressing a major unmet need in T1D with a novel, localized mechanism
• Scalable, modular platform adaptable to future targets and indications
• Elite team with a proven track record in drug development, licensing, and company building

Join us in shaping the future of precision biologics.